E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia

Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh.

Abstract
Background: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. Biomarkers are increasingly being used to distinguish bacterial pneumonia from other causes, to help reduce the duration of antibiotic therapy, and to assess the prognosis of CAP and thereby aiming to complement Pneumonia Severity Index (PSI) and other scores.

Aims & Objective: To compare prognostic utility of procalcitonin (PCT) with existing biomarkers [C-reactive protein (CRP) and total leukocyte count (TLC)] and clinical risk scores (PSI and CURB-65).

Materials and Methods: Fifty patients diagnosed with CAP were included in this study. Baseline serum PCT was measured, which was then stratified according to four predetermined tiers (tier I: <0.1; tier II: 0.1 to <0.25; tier III: 0.25 to <0.5; tier IV: ≥0.5 μg/L). To calculate the severity of pneumonia, patients were classified according to PCT tier, PSI, and CURB-65 scores. Follow-up PCT and reclassification of PSI and CURB-65 were carried out on days 4 and 30.

Results: PCT was more significantly associated with positive bacterial culture than CRP and TLC. Initial PCT level was significantly correlated with TLC (p = 0.044), CRP (p < 0.001), PSI (p < 0.001), and CURB-65 (p = 0.028).

Conclusion: Findings in our study showed that the management of severe CAP would be greatly improved if it were possible to identify, early in the course of disease, those patients who are most likely to develop complications and are at the risk of mortality.

Key words: Pneumonia; Community-Acquired Pneumonia; Procalcitonin; Biomarkers; Clinical Risk Scores


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Sudhir Kumar Agarwal
Articles by Manoj Meena
Articles by Arvind Kumar Misra
Articles by Lalit Prashant Meena
Articles by Mrityunjaya Singh
on Google
on Google Scholar
Article Statistics
 Viewed: 3079
Downloaded: 691
Cited: 0

REFERENCES
1. Rello J. Demographics, guidelines and clinical experience in severe community- acquired pneumonia. Crit Care. 2008;12(Suppl 6):S2.
2. Kaplan V, Clermont G, Griffin MF, Kasal J, Watson RS, Linde-Zwirble WT, et al. Pneumonia: Still the old man’s friend? Arch Intern Med. 2003;163(3):317-23. [DOI via Crossref]    [Pubmed]   
3. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: Final data for 2006. Natl Vital Stat Rep. 2009;57(14):1-134.
4. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2): S27-72.
5. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: Update 2009. Thorax. 2009;64(Suppl 3):iii1-55.
6. Brown SM, Dean NC. Defining and predicting severe community-acquired pneumonia. Curr Opin Infect Dis. 2010;23(2):158-64. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
7. Mira JP, Max A, Burgel PR. The role of biomarkers in community-acquired pneumonia: Predicting mortality and response to adjunctive therapy. Crit Care. 2008;12(Suppl 6):S5.
8. Nazarian DJ, Eddy OL, Lukens TW, Weingart SD, Decker WW. Clinical policy: Critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. Ann Emerg Med. 2009;54(5):704-31. [DOI via Crossref]    [Pubmed]   
9. Niederman MS. Biological markers to determine eligibility in trials for community acquired pneumonia: A focus on procalcitonin. Clin Infect Dis. 2008;47:S127-32.
10. Whang KT, Steinwald PM, White JC, Nylen ES, Snider RH, Simon GL, et al. Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab. 1998;83(9):3296-301. [DOI via Crossref]   
11. Chris-Crain M, Müller B. Procalcitonin and pneumonia: Is it a useful marker? Curr Infect Dis Rep. 2007;9(3):233-40. [DOI via Crossref]   
12. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: Cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600-7. [DOI via Crossref]   
13. Christ-Crain M, Morgenthaler NG, Stolz D, Müller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care. 2006;10:R96.
14. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin- based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial. JAMA. 2009;302:1059-66. [DOI via Crossref]    [Pubmed]   
15. Nylen E, Muller B, Becker K, Snider R. The future diagnostic role of procalcitonin levels: The need for improved sensitivity. Clin Infect Dis. 2003;36:823-4, author reply 6-7.
16. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B, et al. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J. 2011;37:384-92. [DOI via Crossref]    [Pubmed]   
17. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50. [DOI via Crossref]    [Pubmed]   
18. Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med. 2008;52:48-58. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
19. Park JH, Wee JH, Choi SP, Oh SH. The value of procalcitonin level in community-acquired pneumonia in the ED. Am J Emerg Med. 2012;30:1248-54. [DOI via Crossref]    [Pubmed]   
20. Kim JH, Seo JW, Mok JH, Kim MH, Cho WH, Lee K, et al. Usefulness of plasma procalcitonin to predict severity in elderly patients with community-acquired pneumonia. Tuberc Respir Dis (Seoul). 2013;74:207-14 [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   

How to Cite this Article
Pubmed Style

Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. Natl J Physiol Pharm Pharmacol. 2015; 5(1): 28-32. doi:10.5455/njppp.2015.5.120720141


Web Style

Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. http://www.njppp.com/?mno=161490 [Access: December 10, 2018]. doi:10.5455/njppp.2015.5.120720141


AMA (American Medical Association) Style

Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. Natl J Physiol Pharm Pharmacol. 2015; 5(1): 28-32. doi:10.5455/njppp.2015.5.120720141



Vancouver/ICMJE Style

Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. Natl J Physiol Pharm Pharmacol. (2015), [cited December 10, 2018]; 5(1): 28-32. doi:10.5455/njppp.2015.5.120720141



Harvard Style

Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh (2015) A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. Natl J Physiol Pharm Pharmacol, 5 (1), 28-32. doi:10.5455/njppp.2015.5.120720141



Turabian Style

Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. 2015. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. National Journal of Physiology, Pharmacy and Pharmacology, 5 (1), 28-32. doi:10.5455/njppp.2015.5.120720141



Chicago Style

Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. "A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia." National Journal of Physiology, Pharmacy and Pharmacology 5 (2015), 28-32. doi:10.5455/njppp.2015.5.120720141



MLA (The Modern Language Association) Style

Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh. "A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia." National Journal of Physiology, Pharmacy and Pharmacology 5.1 (2015), 28-32. Print. doi:10.5455/njppp.2015.5.120720141



APA (American Psychological Association) Style

Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh (2015) A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. National Journal of Physiology, Pharmacy and Pharmacology, 5 (1), 28-32. doi:10.5455/njppp.2015.5.120720141





Most Viewed Articles
  • Applications of computer science in Pharmacy: An overview
    Shivraj Popat Jadhav, Komal Nikam, Anand Gandhi, Kishor Salunkhe, Narendra Shinde.
    Natl J Physiol Pharm Pharmacol. 2012; 2(1): 1-9
    » Abstract

  • How to calculate sample size in animal studies?
    Hitesh Shah
    Natl J Physiol Pharm Pharmacol. 2011; 1(1): 35-39
    » Abstract

  • Chlorhexidine:The gold standard in chemical plaque control [English]
    Setu mathur, Tanu mathur,Rahul shrivastava, Rohit khatri
    Natl J Physiol Pharm Pharmacol. 2011; 1(2): 45-50
    » Abstract

  • Assessment of Nutritional Status of Pregnant Women Attending the City Tebessa PMI (Algeria) [English]
    Taleb Salima, Kaibi Mounira, Deghboudj Nadjia
    Natl J Physiol Pharm Pharmacol. 2011; 1(2): 97-105
    » Abstract

  • Difference in pulmonary function test among the athletic and sedentary population
    ShobhaRani Vedala, Niranjan Paul, Abhay B Mane
    Natl J Physiol Pharm Pharmacol. 2013; 3(2): 118-123
    » Abstract & References » doi: 10.5455/njppp.2013.3.109-114

  • Analyzing Pharmaceutical Industry [English]
    Veselin Tima Dickov, Dragan Mitrovic, Boris Milan Kuzman
    Natl J Physiol Pharm Pharmacol. 2011; 1(1): 1-8
    » Abstract & References » doi: 10.5455/njppp.2011.1.1-8

  • Antidiabetic activity of alcoholic extract of Neem (Azadirachta Indica) root bark
    Prabhakar Patil, Sudha Patil, Abhay Mane, Sushilkumar Verma
    Natl J Physiol Pharm Pharmacol. 2013; 3(2): 142-146
    » Abstract & References » doi: 10.5455/njppp.2013.3.134-138

  • Second MBBS medical student’s feedback on teaching methodology and evaluation methods in Pharmacology
    Nilesh Chavda, Preeti Yadav, Jay Karan, N. D. Kantharia
    Natl J Physiol Pharm Pharmacol. 2011; 1(1): 23-31
    » Abstract & References » doi: 10.5455/njppp.2011.1.23-31

  • Prophylaxis and Treatment for Leptospirosis: Where are the Evidences?
    Jaykaran Charan, Deepak Saxena, Summaiya Mulla
    Natl J Physiol Pharm Pharmacol. 2012; 2(2): 78-83
    » Abstract & References » doi: 10.5455/njppp.2012.2.78-83

  • How to write a thesis? [English]
    Swapnil s Agarwal, Preeti Yadav, Krishnadutt Chavali, Lavlesh Kumar
    Natl J Physiol Pharm Pharmacol. 2011; 1(2): 86-90
    » Abstract

  • Most Downloaded
  • How to calculate sample size in animal studies?
    Hitesh Shah
    Natl J Physiol Pharm Pharmacol. 2011; 1(1): 35-39
    » Abstract

  • Applications of computer science in Pharmacy: An overview
    Shivraj Popat Jadhav, Komal Nikam, Anand Gandhi, Kishor Salunkhe, Narendra Shinde.
    Natl J Physiol Pharm Pharmacol. 2012; 2(1): 1-9
    » Abstract

  • Chlorhexidine:The gold standard in chemical plaque control [English]
    Setu mathur, Tanu mathur,Rahul shrivastava, Rohit khatri
    Natl J Physiol Pharm Pharmacol. 2011; 1(2): 45-50
    » Abstract

  • Difference in pulmonary function test among the athletic and sedentary population
    ShobhaRani Vedala, Niranjan Paul, Abhay B Mane
    Natl J Physiol Pharm Pharmacol. 2013; 3(2): 118-123
    » Abstract & References » doi: 10.5455/njppp.2013.3.109-114

  • Prophylaxis and Treatment for Leptospirosis: Where are the Evidences?
    Jaykaran Charan, Deepak Saxena, Summaiya Mulla
    Natl J Physiol Pharm Pharmacol. 2012; 2(2): 78-83
    » Abstract & References » doi: 10.5455/njppp.2012.2.78-83

  • Analyzing Pharmaceutical Industry [English]
    Veselin Tima Dickov, Dragan Mitrovic, Boris Milan Kuzman
    Natl J Physiol Pharm Pharmacol. 2011; 1(1): 1-8
    » Abstract & References » doi: 10.5455/njppp.2011.1.1-8

  • A study of oxidative stress in gentamicin induced nephrotoxicity and effect of antioxidant vitamin C in Wistar rats.
    Chetankumar R. Acharya, Hetal N. Thakar, S. K. Vajpeyee
    Natl J Physiol Pharm Pharmacol. 2013; 3(1): 14-20
    » Abstract & References » doi: 10.5455/njppp.2013.3.14-20

  • Second MBBS medical student’s feedback on teaching methodology and evaluation methods in Pharmacology
    Nilesh Chavda, Preeti Yadav, Jay Karan, N. D. Kantharia
    Natl J Physiol Pharm Pharmacol. 2011; 1(1): 23-31
    » Abstract & References » doi: 10.5455/njppp.2011.1.23-31

  • Antidiabetic activity of alcoholic extract of Neem (Azadirachta Indica) root bark
    Prabhakar Patil, Sudha Patil, Abhay Mane, Sushilkumar Verma
    Natl J Physiol Pharm Pharmacol. 2013; 3(2): 142-146
    » Abstract & References » doi: 10.5455/njppp.2013.3.134-138

  • Assessment of Nutritional Status of Pregnant Women Attending the City Tebessa PMI (Algeria) [English]
    Taleb Salima, Kaibi Mounira, Deghboudj Nadjia
    Natl J Physiol Pharm Pharmacol. 2011; 1(2): 97-105
    » Abstract

  • Most Cited Articles
  • A study of oxidative stress in gentamicin induced nephrotoxicity and effect of antioxidant vitamin C in Wistar rats.
    Chetankumar R. Acharya, Hetal N. Thakar, S. K. Vajpeyee
    Natl J Physiol Pharm Pharmacol. 2013; 3(1): 14-20
    » Abstract & References » doi: 10.5455/njppp.2013.3.14-20
    Cited : 8 times [Click to see citing articles]

  • Quercetin improved spatial memory dysfunctions in rat model of intracerebroventricular streptozotocin-induced sporadic Alzheimers disease
    Manouchehr Ashrafpour, Sahar Parsaei, Hamid Sepehri
    Natl J Physiol Pharm Pharmacol. 2015; 5(5): 411-415
    » Abstract & References » doi: 10.5455/njppp.2015.5.2308201563
    Cited : 8 times [Click to see citing articles]

  • A pilot study to evaluate the effect of HAART on gonadal dysfunction in male HIV patients
    Abhishek Pathak, Lalit Prashant Meena, Jaya Chakravarty, Madhukar Rai, Shyam Sundar
    Natl J Physiol Pharm Pharmacol. 2015; 5(1): 33-35
    » Abstract & References » doi: 10.5455/njppp.2015.5.120720142
    Cited : 6 times [Click to see citing articles]

  • Prevalence and risk factors for eating disorders in Indian adolescent females
    Amit A Upadhyah, Rajesh Misra, Deepak N Parchwani, Pankaj B Maheria
    Natl J Physiol Pharm Pharmacol. 2014; 4(2): 153-157
    » Abstract & References » doi: 10.5455/njppp.2014.4.041220131
    Cited : 5 times [Click to see citing articles]

  • Newer anti-platelet and anti-thrombotic drugs on the horizon
    Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi
    Natl J Physiol Pharm Pharmacol. 2013; 3(2): 105-110
    » Abstract & References » doi: 10.5455/njppp.2013.3.090420131
    Cited : 5 times [Click to see citing articles]

  • Rate pressure product predicts cardiovascular risk in type 2 diabetics with cardiac autonomic neuropathy
    Rishu Segan, Vidushi Gupta, Lily Walia, Naveen Mittal
    Natl J Physiol Pharm Pharmacol. 2013; 3(1): 43-47
    » Abstract & References » doi: 10.5455/njppp.2013.3.43-47
    Cited : 4 times [Click to see citing articles]

  • Effects of sixteen weeks exercise training on left ventricular dimensions and function in young athletes
    Sandip M Hulke, Yuganti P Vaidya, Amandeepkour R Ratta
    Natl J Physiol Pharm Pharmacol. 2012; 2(2): 152-158
    » Abstract & References » doi: 10.5455/njppp.2012.2.152-158
    Cited : 4 times [Click to see citing articles]

  • Antidiabetic activity of alcoholic extract of Neem (Azadirachta Indica) root bark
    Prabhakar Patil, Sudha Patil, Abhay Mane, Sushilkumar Verma
    Natl J Physiol Pharm Pharmacol. 2013; 3(2): 142-146
    » Abstract & References » doi: 10.5455/njppp.2013.3.134-138
    Cited : 4 times [Click to see citing articles]

  • Difference in pulmonary function test among the athletic and sedentary population
    ShobhaRani Vedala, Niranjan Paul, Abhay B Mane
    Natl J Physiol Pharm Pharmacol. 2013; 3(2): 118-123
    » Abstract & References » doi: 10.5455/njppp.2013.3.109-114
    Cited : 4 times [Click to see citing articles]

  • Time domain measures of heart rate variability during acute mental stress in Type 2 diabetics- A case control study
    Anupama Deepak, Deepak A N, Shobha Nallulwar, Vitthal Khode
    Natl J Physiol Pharm Pharmacol. 2014; 4(1): 34-38
    » Abstract & References » doi: 10.5455/njppp.2014.4.080720131
    Cited : 4 times [Click to see citing articles]